Clinical trials: Predictive Cancer Model, open to volunteers
Predictive Cancer Model, Pathologic Complete Response
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
The goal of this observational study is to establish a dynamic multi-omics integration model for predicting pathological complete response (pCR) after neoadjuvant treatment in locally advanced (T3-4NxM0) rectal cancer, providing…
- Trial name
- NCT06364371
- Testing
- Medical examination
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Pancreatic Cancer, Circulating Tumor Cell
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed…
- Conditions
- Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model
- Trial name
- LIQUIPANC (NCT06391892)
- Testing
- Neoadjuvant chemotherapy instead of upfront surgery, Upfront surgery
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Elisabethinen Hospital
Paraganglioma, Pheochromocytoma
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system, some which can become metastatic. It is a very rare disease and the tumours are often detected late.
- Conditions
- Paraganglioma, Pheochromocytoma, Genetic Predisposition to Disease, Pathology
- Trial name
- PPGL-Pred (NCT04788927)
- Where
- 2 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Venous Thromboembolism (VTE), Occult Cancer
External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients
This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer.
- Trial name
- CLOVER (NCT07310693)
- Where
- 12 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Infanta Leonor University Hospital
Colorectal Cancer Liver Metastases (CRLM)
AI-Based Prediction of Liver Metastasis in Colorectal Cancer (A Retrospective Study)
This multicenter, retrospective study aims to develop and validate a multimodal deep learning model for predicting the risk of metachronous liver metastasis in patients with stage I-III colorectal cancer following curative…
- Trial name
- NCT07399236
- Testing
- Multimodal Deep Learning Model Analysis
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Tongji Hospital
Gastric Cancer, Immunotherapy
The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
Gastric cancer is one of the cancers with a high mortality rate globally, and its treatment outcomes urgently need to be improved.
- Trial name
- NCT07069842
- Testing
- Multiplex Immunofluorescence Technology, Co-Immunoprecipitation (Co-IP) Technology, Immunohistochemistry
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Changzhi People's Hospital Affiliated to Changzhi Medical College
Cervical Cancer, Radiotherapy
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.
- Conditions
- Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model
- Trial name
- NCT06101966
- Testing
- external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fujian Cancer Hospital
Pseudomyxoma Peritonei, Colorectal Carcinoma
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through…
- Conditions
- Pseudomyxoma Peritonei, Colorectal Carcinoma, Ovarian Carcinoma, Mesothelioma
- Trial name
- PSM (NCT02073500)
- Testing
- Observational study.
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- Oslo University Hospital
Hepatocellular Carcinoma (HCC), Artificial Intelligent
Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
Hepatocellular carcinoma (HCC) is a high-mortality global malignancy with a heavy disease burden in China. Although curative surgical resection improves survival for early-stage HCC patients, the 5-year postoperative recurrence…
- Conditions
- Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy, TACE
- Trial name
- NCT07417800
- Testing
- AI adjuvant therapy
- Where
- China
- Volunteers
- 11,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Melanoma, Cutaneous Squamous Cell Carcinoma
Personalised Immunotherapy Platform
This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours.
- Conditions
- Melanoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- PIP-PREDICT (NCT06536257)
- Testing
- Predictive model
- Where
- 3 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- Melanoma Institute Australia
Cervical Cancer Treated with Pelvic Radiotherapy, Cervical Cancers
Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids
This is a single-arm, single-center, open-label, Phase II study aimed at assessing the efficacy of organoids in predicting the response to radiotherapy and chemotherapy in cervical cancer
- Trial name
- ECCO (NCT06786780)
- Testing
- Drug: Cisplatin
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chongqing University Cancer Hospital
Early Gastric Cancer
A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions
Without high diagnostic efficacy of endoscopic forceps biopsy (EFB) and with low diagnostic efficacy of narrow band imaging (NBI) in novice endoscopists and endoscopists of community hospitals in China, it is urgent to improve…
- Trial name
- NCT02968069
- Testing
- NBI
- Volunteers
- 300 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's…
- Conditions
- Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model, Recurrent Renal Cell Cancer
- Trial name
- NCT06088134
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Mingzhao Xiao
Glioma
The Predictive Value of MRI for Adult-type Diffuse Gliomas
The goal of this observational study is to learn about the diagnostic value of preoperative MRI examination for adult-type diffuse gliomas.
- Trial name
- MRI; glioma; (NCT06572592)
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Thyroid Papillary Carcinoma, Contrast Enhanced Ultrasound
Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound
Similarly, the burden of central lymph node metastasis affects the individualized management of patients with T1N0M0 papillary thyroid carcinoma (PTC): lymph node metastasis is a contraindication to thermal ablation; low-burden…
- Trial name
- NCT07357571
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pheochromocytoma, Paraganglioma
Prospective Cohort Study of Pheochromocytoma/Paraganglioma
The study will enroll patients scheduled for PPGL removal surgery at Peking Union Medical College Hospital. Before surgery, researchers will use a 6-variable model to predict the patient's risk of experiencing severe blood…
- Conditions
- Pheochromocytoma, Paraganglioma, Hemodynamic Instability, Intraoperative Complications
- Trial name
- NCT07516275
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Colorectal Cancer
A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood
This multi-center study aims to develop a precise predictive model for colorectal cancer (CRC) recurrence and metastasis based on multi-omics analysis of portal vein blood.
- Trial name
- PVMRD (NCT06524245)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Peking University Shougang Hospital
Prognostic Cancer Model
Prognostic Significance of ctDNA in HL
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age <60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse…
- Trial name
- NCT06263530
- Where
- 5 sites in Czechia
- Volunteers
- 500 people
- Sponsor
- Interni hematologicka klinika FNKV
Phyllodes Breast Tumor, Artificial Intelligence
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
Breast phyllodes tumor (PT) is a rare fibroepithelial tumor, accounting for 1% to 3% of all breast tumors, categorized by the WHO into benign, borderline, and malignant, based on histopathology features such as tumor border…
- Conditions
- Phyllodes Breast Tumor, Artificial Intelligence, Multiomics, Prognostic Cancer Model
- Trial name
- NCT06286267
- Testing
- imaging
- Where
- 4 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Mass, Breast Cancer
Predicting Breast Cancer With the BRAVE System
Breast cancer predominates among cancer diagnoses in Canadian women. It accounts for around 25% of new cases and contributes to 13% of all cancer-related deaths.
- Trial name
- BRAVE (NCT06498388)
- Testing
- Stiffness measurement by visco-elastography
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Université de Sherbrooke